Serum levels of endocan and endoglin are associated with large-artery atherosclerotic stroke
- 1 March 2018
- journal article
- research article
- Published by Elsevier in Clinica Chimica Acta
- Vol. 478, 157-161
Abstract
No abstract availableKeywords
Funding Information
- Zhejiang Provincial Basic and Public Good Research Plan (LGF18H090019)
- Zhejiang Provincial Medicine and Health Research Foundation (2016KYA186, 2017KY705)
- Taizhou Science and Technology Plan (162yw01, 15yw01)
This publication has 26 references indexed in Scilit:
- Endothelial endoglin is involved in inflammation: role in leukocyte adhesion and transmigrationBlood, 2013
- Oxysterol-Induced Soluble Endoglin Release and Its Involvement in HypertensionCirculation, 2012
- Endoglin as a possible marker of atorvastatin treatment benefit in atherosclerosisPharmacological Research, 2011
- Matrix Metalloproteinase-14 (MT1-MMP)–Mediated Endoglin Shedding Inhibits Tumor AngiogenesisCancer Research, 2010
- Identification of serum endoglin as a novel prognostic marker after acute myocardial infarctionJournal of Cellular and Molecular Medicine, 2008
- Soluble endoglin is an accurate predictor and a pathogenic molecule in pre-eclampsiaNephrology Dialysis Transplantation, 2007
- Endoglin regulates nitric oxide‐dependent vasodilatationThe FASEB Journal, 2004
- Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.Stroke, 1993
- Stroke--1989. Recommendations on stroke prevention, diagnosis, and therapy. Report of the WHO Task Force on Stroke and other Cerebrovascular Disorders.Stroke, 1989
- Measurements of acute cerebral infarction: a clinical examination scale.Stroke, 1989